contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Analyst

Antti Siltanen

Faron Pharmaceuticals is a medical technology company. The company conducts research and development of therapeutic solutions used for the treatment of immune diseases and various organ damage. The largest operations are in North America and Europe, with hospitals and research institutes as the dominant customer base. In addition to the main business, various value-added services are offered. The head office is located in Turku. 

Faron Pharmaceuticals

Faron announced on Monday that it has been awarded an Innovation Passport for the treatment of relapsed/refractory myelodysplastic syndrome (r/r MDS). 

Translation: Original published in Finnish on 12/3/2024 at 7:14 am EET.
Faron&#xa0;<a href="https://www.inderes.se/releases/faron-pharmaceuticals-oy-interactions-with-uk-regulatory-authorities">announced</a> on Monday that it has been awarded an Innovation Passport for the treatment of relapsed/refractory myelodysplastic syndrome (r/r MDS). The Passport is part of the Innovative Licensing and Access Pathway (ILAP) program developed by the UK&apos;s Medicines and Healthcare products Regulatory Agency (MHRA). The Passport will expedite Faron&apos;s interactions with the regulatory agency in the future. In addition, Faron now has approval to conduct the BEXMAB trial in the UK.
<h2>BEXMAB trial extended to the UK</h2>
The ILAP program was introduced by the MHRA in 2021 to give patients quicker access to treatments and therapies for life-threatening and serious conditions. The benefits of the ILAP include enhanced regulatory support from the MHRA and it provides collaborative opportunities with health technology assessment bodies and other stakeholders. The aim of the program is to accelerate the development of medicines and improve patient access to new treatments.
In addition, Faron announced that it has received regulatory approval from the MHRA to conduct the BEXMAB trial in the UK. This approval will allow Faron to recruit UK patients directly, accelerating its research efforts and enhancing the study&apos;s diversity. We anticipate that the regulatory approval will help Faron to complete the BEXMAB trial within the targeted timeframe. Patient recruitment for BEXMAB is expected to be completed in January 2025, allowing for the important result read-out for all r/r MDS patients at the end of Q1&apos;25.

	2023	24e	25e
Revenue	0.0	0.0	0.0
growth-%
EBIT (adj.)	-28.6	-26.1	-29.2
EBIT-% (adj.)	-714,200.00 %	-653,250.00 %	-730,500.00 %
EPS (adj.)	-0.45	-0.28	-0.30
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	-	-	-
EV/EBITDA	-	-	-

Progress for Faron in the UK

BEXMAB trial extended to the UK

Faron Pharmaceuticals

Key Estimate Figures28.08.2024